Pfizer entered a strategic collaboration with Sciwind Biosciences on February 24, 2026, for exclusive commercialization rights to Ecnoglutide injection in Mainland China234
Ecnoglutide, a cAMP-biased GLP-1 receptor agonist, was approved by China's NMPA in January 2026 for type 2 diabetes, with a marketing application for chronic weight management accepted23
The deal includes up to $495 million in upfront, regulatory, and sales milestone payments to Sciwind2345
Clinical data showed 15.1% placebo-adjusted weight loss in Chinese patients, with 92.8% achieving clinically meaningful weight loss23
This partnership advances Pfizer's global metabolic strategy following its $10 billion Metsera acquisition and YaoPharma deal23
Sources:
2. https://www.biospace.com/deals/pfizer-builds-global-glp-1-strategy-with-up-to-495m-sciwind-deal
3. https://www.sciwindbio.com/portal/index/newsdetail/id/123/category_id/5.html
4. https://www.fiercepharma.com/pharma/amid-obesity-push-pfizer-strikes-deal-worth-495m-market-sciwinds-approved-glp-1-china
5. https://www.biopharmadive.com/news/novo-price-cuts-palvella-gossamer-vanda-pfizer-china/812906/